H Alan Tucker
Overview
Explore the profile of H Alan Tucker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
433
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giler M, Tucker H, Foote A, Francis A, Madsen S, Liu Y, et al.
Cytotechnology
. 2025 Feb;
77(2):63.
PMID: 39980838
Supplementary Information: The online version contains supplementary material available at 10.1007/s10616-025-00724-8.
2.
Madsen S, Jones S, Tucker H, Giler M, Muller D, Discher C, et al.
Biotechnol Bioeng
. 2019 Oct;
117(1):223-237.
PMID: 31612990
In vivo mesenchymal stem cell (MSC) survival is relevant to therapeutic applications requiring engraftment and potentially to nonengraftment applications as well. MSCs are a mixture of progenitors at different stages...
3.
Gimble J, Frazier T, Wu X, Alarcon Uquillas A, Llamas C, Brown T, et al.
Plast Reconstr Surg Glob Open
. 2019 Mar;
6(11):e2010.
PMID: 30881803
Background: Processed microvascular tissue (PMVT), a human structural allograft, is derived from lyophilized human tissue containing microcirculatory cellular components. Since PMVT serves as a source of extracellular matrix (ECM), growth...
4.
Madsen S, Russell K, Tucker H, Glowacki J, Bunnell B, OConnor K
Stem Cell Res Ther
. 2017 Oct;
8(1):201.
PMID: 28962588
Background: Mesenchymal stem cells (MSCs) are a mixture of progenitors that are heterogeneous in their regenerative potential. Development of MSC therapies with consistent efficacy is hindered by the absence of...
5.
Strong A, Ohlstein J, Biagas B, Rhodes L, Pei D, Tucker H, et al.
Breast Cancer Res
. 2015 Aug;
17:112.
PMID: 26286584
Introduction: The steady increase in the incidence of obesity among adults has been paralleled with higher levels of obesity-associated breast cancer. While recent studies have suggested that adipose stromal/stem cells...
6.
Russell K, Tucker H, Bunnell B, Andreeff M, Schober W, Gaynor A, et al.
Tissue Eng Part A
. 2013 Apr;
19(19-20):2253-66.
PMID: 23611563
Cellular heterogeneity of mesenchymal stem cells (MSCs) impedes their use in regenerative medicine. The objective of this research is to identify potential biomarkers for the enrichment of progenitors from heterogeneous...
7.
Russell K, Lacey M, Gilliam J, Tucker H, Phinney D, OConnor K
Biotechnol Bioeng
. 2011 May;
108(11):2716-26.
PMID: 21538337
Human mesenchymal stem cells (MSCs) from bone marrow are a heterogeneous ensemble of progenitors and lineage-committed cells, with a broad range of regenerative properties. Ex vivo expansion to produce sufficient...
8.
Tucker H, Bunnell B
Methods Mol Biol
. 2010 Nov;
702:121-31.
PMID: 21082399
One of the hallmark characteristics of human adipose-derived stem cells (hASCs) is their ability to differentiate into cells of mesenchymal lineages. It is also becoming apparent that ASCs can mediate...
9.
Semon J, Nagy L, Llamas C, Tucker H, Lee R, Prockop D
Cell Tissue Res
. 2010 Jun;
341(1):147-58.
PMID: 20563599
Multipotent mesenchymal stromal cells (MSCs) home to damaged tissue by processes partly regulated by integrins. Integrin subunits expressed by MSCs were identified by flow cytometry (FC), immunocytochemistry (IC), and a...
10.
Spees J, Gregory C, Singh H, Tucker H, Peister A, Lynch P, et al.
Mol Ther
. 2004 May;
9(5):747-56.
PMID: 15120336
Adult stem cells from human bone marrow stroma, referred to as mesenchymal stem cells or marrow stromal cells (hMSCs), are attractive candidates for clinical use. The optimal conditions for hMSC...